Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Full IRB Study Title:
Phase II Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
IRB Study ID: 150914
For complete information, please view the study at clinicaltrials.gov
Study Sponsor:
Children's Oncology Group